Sun Pharma Soars 9% on $11.8 Billion Blockbuster Deal for US-listed Organon

Mumbai, April 27: Shares of Sun Pharmaceutical Industries surged in early trade on Monday after the drugmaker announced a blockbuster acquisition of US-listed Organon & Co, in what is being seen as the largest takeover by an Indian pharmaceutical firm.

The stock rose as much as 9% intraday, as investors cheered the strategic expansion, ignoring the massive scale of the transaction. The rally signals a sharp turnaround from recent sessions, where concerns around the size and potential leverage from the deal had dragged sentiment.

As the session progressed, the stock gave up some gains but still traded higher, up over seven percent at Rs 1,744.

At the time of writing, the stock was up over seven percent at Rs 1,744. Source: NSE

All-Cash Deal

Sun Pharma said it will acquire Organon in an all-cash deal valued at about $11.75 billion, including debt, offering $14 per share — a premium of roughly 24% to Organon’s previous closing price. The acquisition significantly expands Sun Pharma’s global footprint, particularly in women’s health, biosimilars and established medicines.

The deal brings with it a portfolio of over 70 products marketed across more than 140 countries, giving Sun Pharma deeper access to key international markets and diversifying its revenue streams. It also marks the company’s entry into biosimilars — a fast-growing segment — while strengthening its presence in developed markets such as the US and Europe.

Post-acquisition, the combined entity is expected to generate around $12.4 billion in annual revenue, positioning Sun Pharma among the top global pharmaceutical players. The move aligns with the company’s strategy to scale up its speciality and innovative portfolio while reducing dependence on traditional generics.

Manageable Impact

Investor sentiment was further buoyed by analyst commentary suggesting that the balance sheet impact may be manageable. The combined entity’s strong cash flows could help Sun Pharma return to a net debt-free position within 3–4 years, despite the initial rise in leverage.

That said, the deal is not without risks. Sun Pharma is expected to take on significant debt to fund the acquisition, with leverage projected at around 2.3 times combined EBITDA post-transaction. Integration challenges and execution risks will also remain key monitorables, particularly given Organon’s existing debt burden and recent financial performance.

Long-term Upside

Still, Monday’s market reaction suggests investors are focusing on the long-term strategic upside rather than near-term balance sheet concerns. The acquisition not only broadens Sun Pharma’s product pipeline but also enhances its global scale — a move that could reshape its positioning in the global pharma landscape.

For now, the Street appears willing to give Sun Pharma the benefit of the doubt, betting that this high-stakes acquisition could turn into a long-term growth engine rather than a balance sheet burden.

Source:

• https://www.nseindia.com/get-quote/equity/SUNPHARMA/Sun-Pharmaceutical-Industries-Limited